Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines

Lung Cancer

Volumn 33, Issue 1, 2001, Pages 27-39

  Loprevite, Maura ^a   Favoni, Roberto E ^a   De Cupis, Alessandra ^a   Pirani, Paolo ^a   Pietra, Gabriella ^b   Bruno, Silvia ^b   Grossi, Francesco ^a   Scolaro, Tindaro ^a   Ardizzoni, Andrea ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Cell cycle; Chemotherapy; In vitro; NSCLC; Radiation

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; RPR 101645; TOPOTECAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOFLUOROMETRY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; COMBINED MODALITY THERAPY; HUMANS; KINETICS; LUNG NEOPLASMS; RADIOTHERAPY; TUMOR CELLS, CULTURED;

EID: 0034948795     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00247-6     Document Type: Article

References (48)

1. Radiation Therapy Oncology Group (RTOG 88-08) Eastern Cooperative Oncology Group (ECOG 4588): preliminary results of a phase III trial in regionally advanced unresectable non small cell lung cancer with minimum three year follow-up (Abstr)
2. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
3. Cytological evidence that Taxol, an antineoplastic agent from Taxus Brevifolia, acts as a mitotic spindle poison
4. Promotion of microtubule assembly in vitro by Taxol
5. Taxol stabilizes microtubules in mouse fibroblast cells
6. Docetaxel (Taxotere®): a review of pre-clinical and clinical experience. Part I: pre-clinical experience
7. Gemcitabine: metabolism, mechanisms of action and self-potentiation
8. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
9. Evaluation of antitumor activity of gemcitabine (2′,2′-difluorodeoxycytidine)
10. The current status of Camptothecin analogues as antitumor agents
11. Investigation of Taxol as a potential radiation sensitizer
12. X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells
13. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells
14. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing
15. Effect of more than one inhibitor
16. In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with diamminedichloroplatinum(II)
17. In vitro studies of taxol as a radiation sensitizer in human tumor cells
18. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol)
19. Radiation and taxol effects on synchronized human cervical carcinoma cells
20. Effect of paclitaxel in combination with radiation on human head and neck cancer cells (2MK-1), cervical squamous cell carcinoma (CaSKi) and breast adenocarcinoma cells (MCF-7)
21. Taxol-enhanced cytotoxic effect of radiation in human promyelocytic leukemia cells: relative resistance of multidrug-resistant HL-60 cells in vitro
22. Taxol: a novel radiation sensitizer
23. Taxol sensitizes human astrocytoma cells to radiation
24. Taxol as a radiation sensitizer: a flow cytometric study
25. Schedule dependence of the interaction of radiation and taxol in HeLa cells
26. Interaction of ionizing radiation with Paclitaxel (Taxol) and Docetaxel (Taxotere) in HeLa and SQ20B cells
27. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells
28. Radiosensitization of human solid tumor cell lines with Gemcitabine
29. Radiosensitization of pancreatic cancer cell lines by 2′, 2′-difluorodeoxycytidine
30. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′, 2′-difluorodeoxycytidine (Gemcitabine)
31. Radiosensitizing potential of Gemcitabine (2′,2′-difluorodeoxycytidine)within the cell cycle in vitro
32. The intensification of the radiotherapic effect on HeLa cells by gemcitabine
33. Interaction of ionizing radiation with Topotecan in two human tumor cell lines
34. The potential of Topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation
35. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells
36. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I
37. Enhancement of tumor radio-response by Irinotecan in human lung tumor xenografts
38. Effects on concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
39. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer
40. Concurrent chemoradiotherapy with Gemcitabine for locally advanced non-small cell lung cancer (NSCLC): preliminary results of a phase II study
41. Result of a trial topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced inoperable non-small cell lung cancer
42. 2/M arrest and phosphorilates Bcl-2
43. Combination of taxanes with radiation: preclinical studies
44. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel
45. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
46. Apoptosis as determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies
47. Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity